drugset / Trial / NCT06162494

Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients

NCT06162494

NaSingle-groupOpen-labelPrevention

Summary

This goal of this study is to assess the safety and immunogenicity of recombinant zoster virus in young adult solid organ transplant recipients. In this study, participants will receive the recombinant zoster vaccine. They will be monitored for adverse events and tested for antibody and cellular immunity.

Timeline

Start
2024-03-18
Primary completion
2027-03-31
Completion
2028-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E Vaccine